Work

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

Year: 2019

Type: article

Abstract: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis and clonal myeloid proliferation which can eventually evolve into acute myeloid leukemia. Dysregulate...

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.1080/10428194.2018.1532509

Authors: John Mascarenhas, Maria R. Baer, Craig Kessler, Elizabeth Hexner, Douglas Tremblay, Leah Price, Lonette Sandy, Rona Weinberg, Heike Pahl, Lewis R. Silverman, Judith D. Goldberg, Heidi Kosiorek, Amylou C. Dueck, Ronald Hoffman

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Abramson Cancer Center, University of Pennsylvania, New York University, New York Blood Center, University of Freiburg, University Medical Center Freiburg, Mayo Clinic in Arizona

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Teva Pharmaceutical Industries, Incyte, National Heart, Lung, and Blood Institute, National Cancer Institute

Awards: G1228257943, G803893432

OpenAlex ID: W2911925296

FWCI: 1.508

Cites: 8

Cited by: 21

Related to: 10